Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Girard

Showing results (51-60 of 74) with videos related to

Pageof 8
Sort By:
Plos One|December 7, 2013
Knowledge and theme discovery across very large biological data sets using distributed queries: a prototype combining unstructured and structured dataUma S Mudunuri, Mohamad Khouja, Stephen Repetski, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 13, 2023
Tumor growth inhibition modeling in patients with second line biliary tract cancer and first line non-small cell lung cancer based on bintrafusp alfa trialsAna-Marija Milenković-Grišić, Nadia Terranova, Diane R Mould, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 5, 2021
Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II doseWenyuan Xiong, Manja Friese-Hamim, Andreas Johne, et al.
Brain Structure & Function|April 10, 2019
In vivo localization of cortical areas using a 3D computerized atlas of the marmoset brainLaurent Risser, Amirouche Sadoun, Muriel Mescam, et al.
Clinical Pharmacology and Therapeutics|September 26, 2019
Changing Body Weight-Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial CarcinomaAna M Novakovic, Justin J Wilkins, Haiqing Dai, et al.
Urology|May 18, 2010
Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumorBenoit You, Ludivine Fronton, Helen Boyle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2021
Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with AvelumabAna-Marija Grisic, Wenyuan Xiong, Lénaïg Tanneau, et al.
Cancer Chemotherapy and Pharmacology|June 30, 2022
Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendationsWenyuan Xiong, Sofia Friberg Hietala, Joakim Nyberg, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 11, 2023
A multistate modeling and simulation framework to learn dose-response of oncology drugs: Application to bintrafusp alfa in non-small cell lung cancerHan Liu, Ana-Marija Milenković-Grišić, Sreenath M Krishnan, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 31, 2021
Pharmacometric modeling and machine learning analyses of prognostic and predictive factors in the JAVELIN Gastric 100 phase III trial of avelumabNadia Terranova, Jonathan French, Haiqing Dai, et al.
Pageof 8

Showing results (51-60 of 74) with videos related to

Sort By:
Pageof 8
Plos One|December 7, 2013
Knowledge and theme discovery across very large biological data sets using distributed queries: a prototype combining unstructured and structured dataUma S Mudunuri, Mohamad Khouja, Stephen Repetski, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 13, 2023
Tumor growth inhibition modeling in patients with second line biliary tract cancer and first line non-small cell lung cancer based on bintrafusp alfa trialsAna-Marija Milenković-Grišić, Nadia Terranova, Diane R Mould, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 5, 2021
Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II doseWenyuan Xiong, Manja Friese-Hamim, Andreas Johne, et al.
Brain Structure & Function|April 10, 2019
In vivo localization of cortical areas using a 3D computerized atlas of the marmoset brainLaurent Risser, Amirouche Sadoun, Muriel Mescam, et al.
Clinical Pharmacology and Therapeutics|September 26, 2019
Changing Body Weight-Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial CarcinomaAna M Novakovic, Justin J Wilkins, Haiqing Dai, et al.
Urology|May 18, 2010
Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumorBenoit You, Ludivine Fronton, Helen Boyle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2021
Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with AvelumabAna-Marija Grisic, Wenyuan Xiong, Lénaïg Tanneau, et al.
Cancer Chemotherapy and Pharmacology|June 30, 2022
Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendationsWenyuan Xiong, Sofia Friberg Hietala, Joakim Nyberg, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 11, 2023
A multistate modeling and simulation framework to learn dose-response of oncology drugs: Application to bintrafusp alfa in non-small cell lung cancerHan Liu, Ana-Marija Milenković-Grišić, Sreenath M Krishnan, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 31, 2021
Pharmacometric modeling and machine learning analyses of prognostic and predictive factors in the JAVELIN Gastric 100 phase III trial of avelumabNadia Terranova, Jonathan French, Haiqing Dai, et al.
Pageof 8